X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

With FDA Approval, Revance With Daxxify Will Rival Botox

Content Team by Content Team
10th September 2022
in FDA Approvals, News
Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

Revance Therapeutics may soon run into an identity problem with a product that is so eagerly awaited that some people mistakenly call it by the name of the firm. Daxxify, Revance’s long-awaited Botox rival, has officially received FDA approval, and the business will now need to establish its brand.

But Revance is unconcerned. CEO Mark Foley stated that people are going to label it a broad range of things. They can create the ideal brand name for the product because it is still so early. The glabellar (frown) lines that are moderate to severe are momentarily removed by the cosmetic procedure. Daxxify is an intravenous neuromodulator, similar to Botox. But the product from Revance is the first to use peptide exchange technology.

The main point of distinction for Daxxify is its durability. Daxxify can last for six months and has been effective for as long as nine months in some individuals, but Botox injections only last for three months. The durational effects of Daxxify were proven in phase 3 trials with 4,200 treatments and 2,700 patients. The trials revealed that a single injection had a significant anti-wrinkle impact.

The largest unmet demand for toxins, according to Foley, is duration. The label is great. They collaborated extensively with the agency to ensure that their label included all 36 weeks of data, allowing them to substantiate these marketing claims. Late-arriving Initially scheduled for an FDA approval in November 2020, Daxxify’s inspection was delayed by the pandemic. After eventually visiting Revance’s production facility, inspectors discovered issues with quality control and record-keeping. The FDA then issued Revance a detailed response letter in October of last year.

The FDA approved the changes in July after Revance resolved all five problems mentioned in the CRL. However, the regulator later noted three additional issues in a Form 483 citation. But for each, the business had an easy fix. Foley said it’s been a long journey to get where they are today. They are ecstatic because this will be the first truly novel neurotoxic to hit the market in more than 30 years.

Of course, the first was Botox, from Allergan, which debuted in 1989. Botox earned $4.7 billion in sales for AbbVie last year across its cosmetic and medicinal uses, and in 2019, the company paid $63 billion to acquire Allergan.

The cost of Daxxify for frown lines has not yet been disclosed by the firm. The business will use a sample strategy for its launch for two quarters. They want to get this into the hands of a select number of doctors so they can learn how to use it and achieve the best results, said Foley. Prior to the wide commercial rollout, they wanted to give that tiny number of users an opportunity to play with it.

Additionally, Revance is looking into the medicinal potential of Daxxify. Cervical Dystonia will submit an application for FDA approval. A phase 2 upper lip spasticity investigation has also been completed.

Previous Post

Trodelvy Returns For Gilead In Treatment Of Breast Cancer

Next Post

FDA Advisors Help Drug Amylyx For ALS, Altering Prior Stance

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
Indian Government Launches Three MSMEs Pharma Programmes

FDA Advisors Help Drug Amylyx For ALS, Altering Prior Stance

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In